Publications by authors named "Yukimasa Hatachi"

Background: There is an increased risk of acute exacerbation of idiopathic interstitial pneumonia when treating patients with advanced non-small cell lung cancer with idiopathic interstitial pneumonia. There is no standard optimal treatment regimen for patients with lung cancer complicated with idiopathic interstitial pneumonia. We aimed to evaluate the efficacy and safety of carboplatin (CBDCA), bevacizumab (Bmab) and weekly paclitaxel (PXT) in patients with idiopathic interstitial pneumonia.

View Article and Find Full Text PDF

Background: Zoledronic acid (ZA) reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from solid tumors. However, the optimal dosing interval of ZA for patients with lung cancer is uncertain.

Methods: We conducted a randomized, open-label, feasibility phase 2 trial at eight Japanese hospitals.

View Article and Find Full Text PDF

High-grade myofibroblastic sarcoma is a rare mesenchymal tumor with a high recurrence and metastatic rate. Few cases of high-grade myofibroblastic sarcomas have been reported. Herein, we report a rare case of undifferentiated, high-grade myofibroblastic sarcoma with an unclear primary site, initially presenting with oral symptoms.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated how age affects the efficacy and safety of standard treatments (fluoropyrimidine and bevacizumab) in older patients (≥75 years) with metastatic colorectal cancer.
  • - In a sample of 102 patients with a median age of 80, typical results showed age didn't significantly impact survival rates (progression-free or overall), though older patients were more likely to experience non-hematologic side effects like fatigue.
  • - Researchers concluded that the effectiveness of the treatments was consistent across ages 75 and older, but highlighted the need to monitor non-hematologic adverse effects as patients get older.
View Article and Find Full Text PDF
Article Synopsis
  • * Patients received different dosages of FOLFIRINOX, finding that a specific dose of irinotecan and a bolus of 5-FU led to significantly better treatment outcomes.
  • * The recommended optimal FOLFIRINOX dosage was identified as oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², and 5-FU 2,400 mg/m², delivered through a 46-hour continuous infusion.
View Article and Find Full Text PDF

Background: Primary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC). Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been introduced recently, the clinical impact of PTL in these treatments is not well understood.

Materials And Methods: We retrospectively evaluated patients with mCRC who were registered in a multicenter observational study (the REGOTAS study).

View Article and Find Full Text PDF

Background/aim: In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events. However, the safety and efficacy of trifluridine/tipiracil in these patients is not clear.

Patients And Methods: The clinical outcomes of trifluridine/tipiracil were retrospectively investigated in patients who were ineligible for regorafenib because of comorbidities.

View Article and Find Full Text PDF

The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The present study evaluated the association between exposure to REG and TFTD and overall survival (OS) in patients with mCRC using data from the REGOTAS study.

View Article and Find Full Text PDF

Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments. Patients with metastatic colorectal cancer treated with REG or FTD/TPI as a salvage-line therapy from May 2014 to December 2017 were included. We retrospectively analyzed long-term survival, safety, and clinical outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • A study evaluated the effectiveness of regorafenib and trifluridine/tipiracil (FTD/TPI) as treatments for metastatic colorectal cancer, recognizing that not all patients benefit equally.
  • The research analyzed data from 489 patients using a multivariate approach to develop a prognostic score based on key clinical factors that could predict overall survival outcomes.
  • This scoring system, which categorizes patients by low, moderate, and high survival benefit, could help identify those who would gain the most from these treatment options.
View Article and Find Full Text PDF
Article Synopsis
  • A 64-year-old man with a gastrointestinal stromal tumor experienced recurrence after stopping imatinib due to lung issues.
  • Initially treated with sunitinib at 50 mg/day, the dose was reduced to 37.5 mg/day due to side effects like gastritis and fever.
  • After four months of disease progression, the dose was increased back to 50 mg/day, resulting in a partial response and better control of adverse events.
View Article and Find Full Text PDF

Background: Alternate-day administration of S-1 is thought to reduce toxicities. This phase II study evaluated S-1 on alternate days combined with bevacizumab as first-line treatment for elderly patients with metastatic colorectal cancer.

Patients And Methods: Eligible patients had histologically proven colorectal adenocarcinoma, measurable metastatic lesions, age ≥ 75 years, Eastern Cooperative Oncology Group performance status ≤ 1, no previous chemotherapy, and refused oxaliplatin- or irinotecan-containing regimens.

View Article and Find Full Text PDF

Introduction: FOLFOXIRI plus bevacizumab has a promising efficacy as first-line systemic chemotherapy for metastatic colorectal cancer (mCRC). This study aimed to evaluate the safety and effectiveness of FOLFOXIRI plus antibodies.

Results: Fifty-five patients were enrolled (median age: 60 years, males: 25, females: 30).

View Article and Find Full Text PDF

Diffuse liver metastasis is a rare pattern of liver metastasis that is associated with hepatic failure and poor prognosis. We experienced 2 cases of acute liver failure due to diffuse metastasis that could not be detected using computed tomography. In , it was difficult to differentiate diffuse metastasis from alcoholic hepatitis.

View Article and Find Full Text PDF

Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable tumors, no standard care exists. While crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is only approved for non-small-cell lung cancer with ALK mutation, it is reportedly effective for other malignant tumors with ALK mutation.

View Article and Find Full Text PDF

Introduction: The neutrophil-to-lymphocyte ratio (NLR) is effective as a predictive factor for lung cancer treated with nivolumab. The objective of this study was to determine the effectiveness of NLR for patients with advanced gastric cancer (AGC) treated with nivolumab.

Methods: This was a multicenter, retrospective study of patients with AGC treated with nivolumab from June 2017 to December 2017.

View Article and Find Full Text PDF

Background: The main purposes of metastatic breast cancer (MBC) treatment are to prolong survival and maintain health-related quality of life (HRQOL). Compliance with the HRQOL assessment can be poor, particularly among patients who receive long-term treatment. One possible solution to overcoming this problem is to engage in real-time home monitoring by having patients report outcomes on their personal electronic devices.

View Article and Find Full Text PDF

Purpose: Optimal salvage chemotherapy for patients with treated advanced/metastatic gastric cancer (AGC) is unknown. Irinotecan is commonly used in Japan. Ramucirumab, a human IgG-1 monoclonal antibody targeting the extracellular domain of VEGF receptor 2, is the first molecularly targeted agent proven to be effective in second-line therapy for AGC in combination with chemotherapy.

View Article and Find Full Text PDF

Background: Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown.

Aim: To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection.

Methods: All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti-HBc antibody and/or positive for anti-HBs antibody), and HBV-DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation.

View Article and Find Full Text PDF

Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have been reported in patients treated with immune checkpoint inhibitors. We report a patient with gastric cancer who received nivolumab after radiotherapy only to experience rapid progression within the irradiation field after the first immunotherapy session.

View Article and Find Full Text PDF

Background: FOLFOXIRI is now regarded as the chemotherapy regimen that offers the best platform for the treatment of colorectal cancer. However, the safety and efficacy of FOLFOXIRI + panitumumab has not been demonstrated. We conducted a phase I study to determine the recommended dose of FOLFOXIRI + panitumumab as first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC).

View Article and Find Full Text PDF

Oxaliplatin-based chemotherapy is widely used to treat advanced cancer. Oxaliplatin-induced hyperammonemic encephalopathy is rarely reported. Here, we report a case of oxaliplatin-induced hyperammonemic encephalopathy occurring after gemcitabine plus oxaliplatin (GEMOX) chemotherapy in a patient with pancreatic cancer.

View Article and Find Full Text PDF

Background: S-1 plus cisplatin is a standard regimen for advanced gastric cancer (AGC) in Asia. The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive AGC. In the HERBIS-1 trial, trastuzumab combined with S-1 plus cisplatin showed promising antitumor activity in patients with HER2-positive AGC.

View Article and Find Full Text PDF

Combination chemotherapy with capecitabine and oxaliplatin for gastric cancer (G-XELOX) is considered as a potentially promising regimen. However, the use of the G-XELOX regimen in Japanese patients has not been investigated to date, and recommended doses of G-XELOX for Japanese patients with metastatic gastric cancer have not been established. The aim of the present study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) for systemic chemotherapy with G-XELOX for metastatic gastric cancer.

View Article and Find Full Text PDF